Momenta Pharmaceuticals (NASDAQ: MNTA) and Idera Pharmaceuticals (NASDAQ:IDRA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.
Valuation & Earnings
This table compares Momenta Pharmaceuticals and Idera Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Momenta Pharmaceuticals||$109.62 million||10.28||-$21.00 million||($0.80)||-18.44|
|Idera Pharmaceuticals||$16.20 million||26.82||-$38.38 million||($0.34)||-6.56|
Institutional and Insider Ownership
93.4% of Momenta Pharmaceuticals shares are held by institutional investors. Comparatively, 24.1% of Idera Pharmaceuticals shares are held by institutional investors. 4.4% of Momenta Pharmaceuticals shares are held by insiders. Comparatively, 12.4% of Idera Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a summary of current ratings and recommmendations for Momenta Pharmaceuticals and Idera Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Momenta Pharmaceuticals presently has a consensus target price of $14.44, suggesting a potential downside of 2.07%. Idera Pharmaceuticals has a consensus target price of $5.40, suggesting a potential upside of 142.15%. Given Idera Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Idera Pharmaceuticals is more favorable than Momenta Pharmaceuticals.
Risk & Volatility
Momenta Pharmaceuticals has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, Idera Pharmaceuticals has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500.
This table compares Momenta Pharmaceuticals and Idera Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Idera Pharmaceuticals beats Momenta Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company’s Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company’s programs include M254, M281 (Anti-FcRn candidate) and M230.
Idera Pharmaceuticals Company Profile
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.